{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:02:48Z","timestamp":1790874168152,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,1]],"date-time":"2027-10-01T00:00:00Z","timestamp":1822348800000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.07.010","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:00:49Z","timestamp":1784790049000},"page":"640-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-4151","authenticated-orcid":false,"given":"Anthony M.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.07.010_bib0001","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0002","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects","volume":"11","author":"James","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.07.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0005","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0006","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0007","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0009","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2026.07.010_bib0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/hon.2509","article-title":"Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients","volume":"36","author":"Polverelli","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0011","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2026.07.010_bib0012","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0013","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0014","series-title":"Ruxolitinib. Package insert","year":"2026"},{"key":"10.1016\/j.clml.2026.07.010_bib0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-020-00392-1","article-title":"Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis","volume":"11","author":"Palandri","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.07.010_bib0016","article-title":"Discontinuation syndrome with JAK2 selective agents: case presentation and mechanistic insights","volume":"8","author":"Handa","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0017","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3324\/haematol.2025.288654","article-title":"JAK inhibitor selection in challenging scenarios of myelofibrosis: a review","volume":"111","author":"Vachhani","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0018","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3324\/haematol.2023.283106","article-title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","volume":"109","author":"Mesa","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0019","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.07.010_bib0021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0022","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0023","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of Momelotinib versus Ruxolitinib in Janus Kinase inhibitor-naive patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0024","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.07.010_bib0026","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0027","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0028","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/10428194.2024.2346733","article-title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.07.010_bib0029","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ajh.70203","article-title":"Post-FDA approval experience with momelotinib in JAK inhibitor-naive myelofibrosis: focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy","volume":"101","author":"Tefferi","year":"2026","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.13262","article-title":"Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis","volume":"169","author":"Abdelrahman","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0031","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0032","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1007\/s00277-024-05908-4","article-title":"MoReLife: real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients","volume":"103","author":"Jilg","year":"2024","journal-title":"Ann Hematol"},{"issue":"supplement 1","key":"10.1016\/j.clml.2026.07.010_bib0033","first-page":"4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with Fedratinib","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0034","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0036","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kroger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0037","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0038","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0039","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0040","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0041","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0042","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced International prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0043","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2024014368","article-title":"Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis","volume":"9","author":"Luque Paz","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0044","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0045","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/bloodadvances.2023009886","article-title":"A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR\/EBMT analysis","volume":"7","author":"Tamari","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0046","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/hon.2429","article-title":"Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study","volume":"36","author":"Palandri","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0047","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0048","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1002\/cncr.35489","article-title":"Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: the RUX-MF real-World study","volume":"130","author":"Palandri","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.07.010_bib0049","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2026.07.010_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","article-title":"Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: results from a multicentre study on 284 patients","volume":"74","author":"Palandri","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.07.010_bib0051","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2020.1845334","article-title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.07.010_bib0052","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0053","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0054","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0055","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0056","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0057","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0058","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0059","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ejh.14321","article-title":"Pacritinib response is associated with overall survival in Myelofibrosis: PERSIST-2 landmark analysis of survival","volume":"114","author":"Ajufo","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0060","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.07.010_bib0061","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0062","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.07.010_bib0063","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0064","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0065","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kroger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0066","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","article-title":"Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation","volume":"24","author":"Kroger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.07.010_bib0067","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0068","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0069","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0070","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/cncr.34851","article-title":"The role of therapy in the outcome of patients with myelofibrosis","volume":"129","author":"Masarova","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.07.010_bib0071","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0072","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS7080","article-title":"ReTHINK: a randomized, double-blind, placebo controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients","volume":"34","author":"Passamonti","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0073","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133331","article-title":"Association of myelofibrosis phenotypes with clinical manifestations, molecular profiles, and treatments","volume":"15","author":"Chifotides","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2026.07.010_bib0074","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.07.010_bib0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2026.07.010_bib0076","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0077","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0078","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","article-title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","volume":"57","author":"Al-Ali","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.07.010_bib0079","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41375-021-01261-x","article-title":"Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study","volume":"35","author":"Cervantes","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0081","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0082","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.07.010_bib0083","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.07.010_bib0084","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1182\/blood-2025-5581","article-title":"Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: post hoc analyses of the simplify-1 and momentum trials","volume":"146","author":"Palandri","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2026.02.004","article-title":"Spleen volume reduction and transfusion independence with momelotinib versus ruxolitinib and associated overall survival with momelotinib in JAK inhibitor-naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1","volume":"26","author":"Palandri","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2026.07.010_bib0086","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.27659","article-title":"Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic syndromes","volume":"100","author":"Gangat","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0087","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0088","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Hernandez-Boluda","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0089","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ejh.13910","article-title":"Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia","volume":"110","author":"Inzoli","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0090","first-page":"741","article-title":"Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease","volume":"15","author":"Horowitz","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clml.2026.07.010_bib0091","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0092","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2010-12-325589","article-title":"Comparison of thalidomide and lenalidomide as therapy for myelofibrosis","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.07.010_bib0093","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/diseases10040085","article-title":"A new tool for the treatment of anemia related to beta-thalassemia, myelodysplastic syndromes and primary myelofibrosis","volume":"10","author":"Hatzimichael","year":"2022","journal-title":"Diseases"},{"key":"10.1016\/j.clml.2026.07.010_bib0094","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0095","series-title":"European Hematology Association 2026 Congress","article-title":"Efficacy and safety of Luspatercept in patients with myelofibrosis on Janus kinase inhibitors who require red blood cell transfusions: primary analysis of the phase 3 independence trial","author":"Passamonti","year":"2026"},{"key":"10.1016\/j.clml.2026.07.010_bib0096","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/blood-2025-2825","article-title":"A retrospective study to assess real-world treatment patterns and coutomes in luspatercept-treated patients wtih myelofibrosis-associated anemia who required red blood cell transfusion in the United States","volume":"146","author":"Hobbs","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0097","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0098","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0099","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0100","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.07.010_bib0101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.16_suppl.6575","article-title":"Treatment patterns and outcomes in pacritinib-treated patients with MF and higher platelet count: MY-PAC study","volume":"44","author":"Tremblay","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0102","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000963","article-title":"Momelotinib in Myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials","volume":"7","author":"Kiladjian","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2026.07.010_bib0103","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.07.010_bib0104","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2217\/fon-2021-1358","article-title":"Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review","volume":"18","author":"Passamonti","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2026.07.010_bib0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13696998.2020.1741381","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clml.2026.07.010_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.107719","article-title":"Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: the Italian RUX-MF multicenter study","volume":"154","author":"Palandri","year":"2025","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2026.07.010_bib0107","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.07.010_bib0108","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/j.clml.2025.02.015","article-title":"Disease phenotype significantly influences the outcome after discontinuation of Ruxolitinib in chronic phase myelofibrosis","volume":"25","author":"Palandri","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.010_bib0109","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2025-5600","article-title":"An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis","volume":"146","author":"Kuykendall","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0110","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2023-179369","article-title":"Preclinical evaluation of INCB160058-a novel and potentially disease-modifying therapy for jak2v617f mutant myeloproliferative neoplasms","volume":"146","author":"Stubbs","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2015.06.006","article-title":"CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms","volume":"28","author":"Meyer","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.07.010_bib0112","series-title":"European Hematology Association Congress 2026","article-title":"Results of Ajx-101, a phase 1 clinical trial of the type ii Jak2 inhibitor Aj1-11095, in patients with myelofibrosis who have been failed by a type I Jak2 inhibitor","author":"Mascarenhas","year":"2026"},{"key":"10.1016\/j.clml.2026.07.010_bib0113","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/cas.13327","article-title":"Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms","volume":"108","author":"Araki","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2026.07.010_bib0114","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood-2025-484","article-title":"Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA0033989 as monotherapy or in combination with ruxoitinib in patients with myelofibrosis: preliminary results from dose escalation of two global phase 1 studies","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0115","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2023-173430","article-title":"Discovery of JNJ-88549968, a novel, first-in-class, CALRmutxCD3 T-cell redirecting antibody for the treatment of myeloproliferative neoplasms","volume":"142","author":"Kuchnio","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0116","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0117","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2022.12.014","article-title":"SOHO State of the art updates and next questions: novel therapeutic strategies in development for myelofibrosis","volume":"23","author":"Chifotides","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.07.010_bib0118","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","article-title":"Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment","volume":"37","author":"Gisslinger","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.07.010_bib0119","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2024-201729","article-title":"Hematological improvement and other clinical benefits of Elritercept as monotherapy and in combination with Ruxolitinib in participants with myelofibrosis from the ongoing phase 2 restore trial","volume":"144","author":"Harrison","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.07.010_bib0120","series-title":"European Hematology Association Congress 2026","article-title":"Rally-MF: initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis","author":"Gangat","year":"2026"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:17:28Z","timestamp":1790871448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":120,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002156"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions| Individualizing Treatment Selection in Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}